Actively Recruiting
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-05-06
964
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
CONDITIONS
Official Title
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 218 years or older
- Histologically confirmed HER2-positive breast cancer (IHC 3+ or IHC 2+ with ISH+)
- Expected to receive pyrotinib-containing regimens for neoadjuvant or metastatic/unresectable breast cancer
- Have had no more than one prior line of anti-HER2 therapy during recurrent/metastatic stage
- Ability to operate a mobile phone and read independently
- Psychologically and physically suitable for participation as judged by investigator
You will not qualify if you...
- History of cognitive impairment
- Severe visual or auditory impairments
- Prior use of pyrotinib
- Pregnancy, lactation, or intention to conceive
- Ineffective cognitive-behavioral interventions within past year
- Participation in other clinical trials within 1 month prior to screening
- Investigator judgment of unsuitability due to psychological or physical conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
J
Jiani Wang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here